| Multiple Myeloma

Carvykti vs Tecvayli

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Carvykti vs Tecvayli with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecvayli has a higher rate of injection site reactions vs Carvykti based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecvayli but not Carvykti, including UnitedHealthcare

Category

Carvykti

Tecvayli

At A Glance

RouteIV infusion

FrequencySingle infusion

ClassBCMA-directed CAR-T cell therapy

RouteSC injection

FrequencyWeekly to every 4 weeks

ClassBCMA-directed CD3 T-cell engager

Indications

Multiple Myeloma

Multiple Myeloma

Dosing

Multiple Myeloma 0.5-1.0x10^6 CAR-positive viable T cells/kg IV (max 1x10^8 cells) as a single infusion, administered 2-4 days after lymphodepleting chemotherapy (cyclophosphamide 300 mg/m^2 IV and fludarabine 30 mg/m^2 IV daily for 3 days); premedicate with acetaminophen and an H1-antihistamine 30-60 minutes prior to infusion.

Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.

Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.

Contraindications

—

Drug Interactions

26View drug interactions

27View drug interactions

Adverse Reactions

Most common (>20%) Pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, vomiting

Serious Pneumonia, cytokine release syndrome, sepsis, encephalopathy, viral infection, cranial nerve palsies

Postmarketing T cell malignancies including T-cell lymphoma, immune effector cell-associated enterocolitis and gastrointestinal perforation, infusion related reactions, JC virus progressive multifocal leukoencephalopathy

Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased

Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy

Pharmacology

CARVYKTI is a BCMA-directed, genetically modified autologous T cell immunotherapy that reprograms a patient's own T cells with a transgene encoding a CAR featuring two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain, and a CD3-zeta signaling domain; upon binding to BCMA-expressing cells, the CAR promotes T cell activation, expansion, and elimination of target cells.

Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Carvykti